Abbott Laboratories (ABT) Revenue — Quarter Ended Jun 30, 2023
Revenue for the quarter grew compared to the immediately preceding quarter, but declined compared to the same quarter one year earlier. The filing context does not provide explicit commentary on revenue performance.
Key takeaway
Quarter ended Jun 30, 2023 · FY2023 Q2
Revenue for the quarter grew compared to the immediately preceding quarter, but declined compared to the same quarter one year earlier. The filing context does not provide explicit commentary on revenue performance.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$10B
Revenue reported for this quarter.
Quarter-over-quarter
+2.4%
Change from the immediately preceding quarter.
Year-over-year
-11.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$40.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2022 | $10.4B | -4.7% |
| Dec 31, 2022 | $10.1B | -12.0% |
| Mar 31, 2023 | $9.7B | -18.1% |
| Jun 30, 2023 | $10B | -11.4% |
Revenue performance
The reported revenue increased from the prior quarter, yet fell relative to the year-ago period.
Quarterly comparison
The sequential rise contrasts with the year-over-year decline, indicating a mixed trend.
What to watch
The filing noted a decrease in cash and cash equivalents and an increase in inventory, factors that could influence future results.